{"id":"pitolisant-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Anxiety"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Irritability"}]},"_chembl":{"chemblId":"CHEMBL4164059","moleculeType":"Small molecule","molecularWeight":"332.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking H3 autoreceptors on histaminergic neurons in the hypothalamus, pitolisant removes negative feedback inhibition and enhances histamine neurotransmission. This increased histaminergic signaling promotes arousal and wakefulness, making it effective for conditions characterized by excessive daytime sleepiness. The drug crosses the blood-brain barrier and acts centrally without significant peripheral effects.","oneSentence":"Pitolisant is a selective histamine H3 receptor antagonist that increases histamine release in the brain to promote wakefulness.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:11.848Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Narcolepsy type 1 and type 2"},{"name":"Excessive daytime sleepiness associated with narcolepsy"}]},"trialDetails":[{"nctId":"NCT06366464","phase":"PHASE3","title":"A Study of Pitolisant in Patients With Prader-Willi Syndrome","status":"RECRUITING","sponsor":"Harmony Biosciences Management, Inc.","startDate":"2024-05-28","conditions":"Prader-Willi Syndrome","enrollment":134},{"nctId":"NCT07219485","phase":"PHASE3","title":"A Study of Pitolisant in Participants With Prader-Willi Syndrome","status":"ENROLLING_BY_INVITATION","sponsor":"Harmony Biosciences Management, Inc.","startDate":"2025-08-20","conditions":"Prader-Willi Syndrome","enrollment":150},{"nctId":"NCT04257929","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harmony Biosciences Management, Inc.","startDate":"2020-12-09","conditions":"Prader-Willi Syndrome","enrollment":65},{"nctId":"NCT07051252","phase":"PHASE1","title":"A Study of HBS-201 (Pitolisant Delayed-release)","status":"COMPLETED","sponsor":"Harmony Biosciences Management, Inc.","startDate":"2025-05-21","conditions":"Narcolepsy","enrollment":46},{"nctId":"NCT05458128","phase":"PHASE3","title":"A Long-Term Safety and Effectiveness Study to Evaluate Pitolisant in Adult Patients With Idiopathic Hypersomnia","status":"COMPLETED","sponsor":"Harmony Biosciences Management, Inc.","startDate":"2022-08-19","conditions":"Idiopathic Hypersomnia, Excessive Daytime Sleepiness","enrollment":119},{"nctId":"NCT05953389","phase":"PHASE2","title":"Proof of Concept Study on Pitolisant Effect on Autism Spectrum Disorders in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bioprojet","startDate":"2023-12-20","conditions":"Autism Spectrum Disorder","enrollment":62},{"nctId":"NCT02611687","phase":"PHASE3","title":"Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period","status":"COMPLETED","sponsor":"Bioprojet","startDate":"2016-06-06","conditions":"Narcolepsy With Cataplexy, Narcolepsy Without Cataplexy","enrollment":110},{"nctId":"NCT04886518","phase":"PHASE2","title":"Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1","status":"COMPLETED","sponsor":"Harmony Biosciences Management, Inc.","startDate":"2021-06-28","conditions":"Myotonic Dystrophy 1, Excessive Daytime Sleepiness","enrollment":30},{"nctId":"NCT05156047","phase":"PHASE3","title":"A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia","status":"COMPLETED","sponsor":"Harmony Biosciences Management, Inc.","startDate":"2022-05-25","conditions":"Idiopathic Hypersomnia","enrollment":214},{"nctId":"NCT05849675","phase":"NA","title":"Pitolisant Effects on Affect and Cognition Exploratory Study (PEACE Study)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2023-04-01","conditions":"Anhedonia, Cognitive Function","enrollment":58},{"nctId":"NCT05223166","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy and Safety of Pitolisant in the Treatment of EDS in Patients With OSA","status":"COMPLETED","sponsor":"Citrine Medicine Limited","startDate":"2022-04-12","conditions":"Excessive Daytime Sleepiness","enrollment":240},{"nctId":"NCT03433131","phase":"","title":"Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy","status":"NO_LONGER_AVAILABLE","sponsor":"Harmony Biosciences Management, Inc.","startDate":"","conditions":"Narcolepsy Without Cataplexy, Narcolepsy With Cataplexy","enrollment":""},{"nctId":"NCT02978651","phase":"PHASE3","title":"Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness","status":"WITHDRAWN","sponsor":"Bioprojet","startDate":"","conditions":"Excessive Daytime Sleepiness, Obstructive Sleep Apnea","enrollment":""},{"nctId":"NCT03152123","phase":"PHASE1","title":"Determination the Abuse Potential of Pitolisant in Healthy, Non-Dependent Recreational Stimulant Users","status":"COMPLETED","sponsor":"Bioprojet","startDate":"2017-03-15","conditions":"Healthy, Drug Abuse","enrollment":43},{"nctId":"NCT01638403","phase":"PHASE3","title":"Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.","status":"COMPLETED","sponsor":"Bioprojet","startDate":"2010-11","conditions":"Treatment of Excessive Daytime Sleepiness in Narcolepsy","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["pitolisant"],"phase":"phase_3","status":"active","brandName":"Pitolisant tablet","genericName":"Pitolisant tablet","companyName":"Harmony Biosciences Management, Inc.","companyId":"harmony-biosciences-management-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pitolisant is a selective histamine H3 receptor antagonist that increases histamine release in the brain to promote wakefulness. Used for Narcolepsy type 1 and type 2, Excessive daytime sleepiness associated with narcolepsy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}